Active — Not RecruitingPhase 2

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

United States703 participantsStarted 2022-07-22

Plain-language summary

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of Crohn's disease (CD) for at least 3 months prior to baseline * Confirmed diagnosis of moderate to severe CD as assessed by Crohn'

What they're measuring

Percentage of Participants with Clinical Remission at Week 48

Timeframe: Week 48

Percentage of Participants with Endoscopic Response at Week 48

Timeframe: Week 48

Trial details

NCT IDNCT05242471

SponsorJanssen Research & Development, LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-05-23

View on ClinicalTrials.gov More Crohn's Disease trials